0001745114-26-000009
SEC filingMolecular Partners AG (MOLN), a clinical-stage biotech focused on DARPin therapeutics for oncology, reported FY 2025 results with no revenues, down from $5.0M in 2024 and $7.0M in 2023, all from Novartis radioligand collaboration which ended in Q3 2024. Total operating expenses decreased 12% YoY to $58.1M, driven by lower R&D spend of $40.2M (vs $48.6M prior year) amid program prioritization, including MP0533 and MP0317. SG&A expenses fell 13% to $15.2M. Restructuring costs of $2.7M reflected headcount reduction of 34 positions. Operating loss narrowed to $58.1M from $61.2M. Net finance result swung to -$3.5M loss from $7.2M gain, due to FX losses. Net loss was $61.7M or CHF -2.00/share, vs $54.0M loss prior year. Cash burn from operations was $51.3M, with $72.5M investing inflow from time deposits. Cash and equivalents ended at $82.7M plus $10.4M deposits, supporting runway into 2028. Balance sheet shows $102.1M assets, $80.3M equity. FY25 highlights include MP0712 Phase 1/2a start and Orano Med expansion to 10 RDT programs.
Molecular Partners AG reported FY25 net loss of $61.7M, widening 14% YoY from $54.0M despite 12% lower operating expenses of $58.1M vs $66.2M. No revenues recorded (down 100% from $5.0M FY24 Novartis collaboration), reflecting end of radioligand research phase. R&D expenses fell to $40.2M (17% YoY decline), driven by efficiencies in MP0533/MP0317 and restructuring. SG&A down 13% to $15.2M. Cash burn moderated to $51.3M operating outflow. Balance sheet remains solid with $102.1M assets, $80.3M equity, $82.7M cash/equivalents supporting runway to 2028. Strategic focus on oncology pipeline including MP0712 Phase 1/2a initiation and Orano Med expansion.
Revenues were $0 in FY25, a full-year decline from $5.0M FY24 and $7.0M FY23, entirely from Novartis radioligand collaboration (ended Q3 2024). No geographic or segment breakdown disclosed; all prior revenues from Switzerland-based Novartis. No new revenue sources in FY25; future potential from Orano Med co-development (DLL3 RDT) and milestones, but none recognized.
No gross profit applicable (zero revenue). Operating margin N/A but operating loss improved 5% to $58.1M. Cost structure: personnel 60% of opex ($34.7M), R&D consumables/projects 19% ($11.2M). Restructuring $2.7M (5% of opex) from headcount cut (134 FTEs YE25 vs 159 FY24). Non-cash items $3.9M (share-based/pension). FY25 reflects efficiency gains amid pipeline prioritization.
Operating cash use $51.3M (improved from $59.2M FY24). Investing inflow $72.5M from time deposit maturities net of $0.7M capex. Financing outflow $1.1M (leases). Net cash increase $18.8M to $82.7M (+$10.4M deposits). Total liquidity $93.1M. Balance sheet: $102.1M assets (95% current), $80.3M equity (-43% YoY from restructuring/cumulative losses -$311.8M). No debt; liabilities $21.8M (pensions $8.1M, leases $3.6M).
Management affirms cash runway into 2028. Priorities: MP0712 Phase 1/2a data 2026, MP0726 FIH imaging, Switch-DARPin lead nomination H1 2026. Orano Med co-dev (10 programs), Eckert & Ziegler TAT agreement. Risks: clinical trial delays, funding needs, competition in radioligands/TCEs. No quantitative guidance; focus on oncology milestones.